ArticleOphthalmology and therapy2026
Fast Progressors in Primary Open-Angle Glaucoma: A 5-Year Visual Field Index-Based Classification in a Real-World Cohort.
Article in Ophthalmology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
introductionThe purpose of this study was to investigate the effect of visual field index (VFI) of identifying especially "fast visual field (VF) progressors" in patients with primary open angle glaucoma (POAG) and to analyze the risk factors.
methodsFast progression was defined as VFI decline worse than -4.6%/year or mean deviation (MD) worse than -1 decibel (dB)/year. Moderately rapid progression (MRP) was defined using cohort-derived cutoffs (VFI worse than -1.016%/year; MD worse than -0.44 dB/year). Proportions of fast progression and MRP were compared between VFI- and MD-based criteria and across baseline disease stages. Longitudinal VFI change was further analyzed as a continuous outcome using linear mixed-effects models (LMM) with random intercepts and slopes for eyes nested within patients.
resultsA total of 162 participants (315 eyes) were included; 94 (58.02%) were male and 68 (41.98%) were female. VFI indicated a fast progression rate of 0.92% and MRP rate of 20.63%, whereas MD yielded 2.75% and 23.49%, respectively. The proportion of eyes classified as VFI-defined MRP increased markedly with advancing disease stage (p < 0.001). MD-confirmed MRP showed a concordant stage-dependent trend but did not reach statistical significance. In multivariable analysis, worse baseline MD, thinner central corneal thickness, lower spherical equivalent, and older age were independently associated with a steeper annual VFI decline.
conclusionsIn this long-term treated POAG cohort, VFI-defined fast progression was rare; however, VFI-based criteria provided statistically significant stage-dependent discrimination of clinically relevant progression. The results support incorporating longitudinal VFI modeling into routine-care datasets to better identify eyes at higher risk of meaningful functional loss over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.